AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15634273 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 50 mg twice daily
Number of subjects: 1973
Study 15634273 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg twice daily
Number of subjects: 1973
Study 15634273 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 300 mg once daily
Number of subjects: 1973
Study 15634273 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 225 mg twice daily
Number of subjects: 1973
Study 15634273 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (40 mg once daily)
Number of subjects: 1973
Study 16036023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular assist devices as destination therapy
Number of subjects: 0
Study 16036023 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller, more durable mechanical assist devices
Number of subjects: 0
Study 10996579 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway bacterial load
Number of subjects: 160
Study 10996579 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial load of 10(6) to 10(7) CFU/mL
Number of subjects: 160
Study 10996579 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial load of 10(7) to 10(8) CFU/mL
Number of subjects: 160
Study 10996579 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial load of 10(8) or greater CFU/mL
Number of subjects: 160
Study 10996579 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonization with Pseudomonas aeruginosa
Number of subjects: 160
Study 10996579 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonization with nontypeable Hemophilus influenzae
Number of subjects: 160
Study 9115022 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator drugs
Number of subjects: 12301
Study 9115022 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 12301
Study 8461646 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed information about potential complications
Number of subjects: 96
Study 8461646 — intervention group
Group type: COMPARATOR
Intervention: Simple explanation of the facts
Number of subjects: 96
Study 3546151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (100 mg, b.i.d. for 7 days)
Number of subjects: 35
Study 3546151 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (250 mg, b.i.d. for 7 days)
Number of subjects: 35
Study 30379815 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 100
Study 30379815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27368279 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 20
Study 27368279 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 20
Study 24880581 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing therapy (n=10)
Number of subjects: 20
Study 24880581 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (n=10)
Number of subjects: 20
Study 22520655 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthier, alternative menu at a budget supermarket
Number of subjects: 0
Study 22520655 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthier, alternative menu at a mid-range supermarket
Number of subjects: 0
Study 22520655 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from unhealthy mid-range supermarket menu to healthier, budget-outlet alternative
Number of subjects: 0
Study 22520655 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthier, alternative menu on the high street
Number of subjects: 0
Study 22520655 — intervention group
Group type: COMPARATOR
Intervention: Existing diet at a budget supermarket
Number of subjects: 0
Study 20424140 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid heparin infusion (LHI) inducing physiological elevations of FFAs
Number of subjects: 28
Study 20424140 — intervention group
Group type: COMPARATOR
Intervention: Discontinued insulin infusion
Number of subjects: 28
Study 20424140 — intervention group
Group type: COMPARATOR
Intervention: Continuous insulin supply
Number of subjects: 28
Study 18793446 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted physiotherapy (8 individual sessions over 12 weeks, home exercise program 4 times/week)
Number of subjects: 90
Study 18793446 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapist-delivered OA education control treatment (8 individual sessions over 12 weeks)
Number of subjects: 90
Study 16182685 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dietary supplements
Number of subjects: 13
Study 16182685 — intervention group
Group type: COMPARATOR
Intervention: Dietary counseling
Number of subjects: 13
Study 12601099 — intervention group
Group type: EXPERIMENTAL
Intervention: (11)C-WAY 100635 PET in patients with PD
Number of subjects: 23
Study 10855138 — intervention group
Group type: EXPERIMENTAL
Intervention: Taught session
Number of subjects: 12
Study 10855138 — intervention group
Group type: COMPARATOR
Intervention: Self-study group
Number of subjects: 12
Study 8580688 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenmai injection (SMI)
Number of subjects: 63
Study 8580688 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study 2232625 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol (40 mg)
Number of subjects: 12
Study 2232625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 159057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (30 mg)
Number of subjects: 10
Study 159057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29771596 — intervention group
Group type: EXPERIMENTAL
Intervention: ExPEC4V vaccine (4, 8, and 16 µg PS/serotype)
Number of subjects: 48
Study 29771596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 26659916 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lenalidomide and dexamethasone
Number of subjects: 1613
Study 26659916 — intervention group
Group type: COMPARATOR
Intervention: Melphalan, prednisone, and thalidomide
Number of subjects: 1613
Study 23109138 — intervention group
Group type: EXPERIMENTAL
Intervention: Group support (constructed support)
Number of subjects: 305
Study 23109138 — intervention group
Group type: EXPERIMENTAL
Intervention: Family support (naturalistic support)
Number of subjects: 305
Study 21998259 — intervention group
Group type: EXPERIMENTAL
Intervention: AHR strategy (titrating inhaled corticosteroid against mannitol PD(10))
Number of subjects: 164
Study 21998259 — intervention group
Group type: EXPERIMENTAL
Intervention: AHR strategy
Number of subjects: 164
Study 21998259 — intervention group
Group type: COMPARATOR
Intervention: Control group (reference strategy)
Number of subjects: 164
Study 20480225 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 800 mg/day during cycles 5-8
Number of subjects: 340
Study 20480225 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (8 mg/kg then 6 mg/kg IV every 3 weeks)
Number of subjects: 340
Study 20480225 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (control for HER2-negative)
Number of subjects: 340
Study 20480225 — intervention group
Group type: COMPARATOR
Intervention: No additional preoperative treatment (control for HER2-positive)
Number of subjects: 340
Study 18705755 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Nigella sativa seed extract twice a day
Number of subjects: 0
Study 18705755 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg Nigella sativa seed extract twice a day
Number of subjects: 0
Study 18705755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15744449 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxy vitamin D levels below 20 ng/ml
Number of subjects: 986
Study 15744449 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxy vitamin D levels below 30 ng/ml
Number of subjects: 986
Study 15744449 — intervention group
Group type: COMPARATOR
Intervention: High mean 25OHD levels
Number of subjects: 986
Study 14710908 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 units of BTX‐A injected into each nasal cavity (total 40 units)
Number of subjects: 34
Study 14710908 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 units of BTX‐A injected into each nasal cavity (total 60 units)
Number of subjects: 34
Study 14710908 — intervention group
Group type: COMPARATOR
Intervention: 2 ml of isotonic saline (placebo)
Number of subjects: 34
Study 10070048 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hyperglycemia (approximately 10 mmol/l)
Number of subjects: 9
Study 10070048 — intervention group
Group type: COMPARATOR
Intervention: Euglycemia (approximately 4 mmol/l)
Number of subjects: 9
Study 7668024 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg erythromycin q.i.d.
Number of subjects: 10
Study 7668024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7668024 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg erythromycin i.v. (single dose)
Number of subjects: 10
Study 2107773 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA and glyceryl trinitrate ointment
Number of subjects: 100
Study 2107773 — intervention group
Group type: COMPARATOR
Intervention: EMLA
Number of subjects: 100
Study 2107773 — intervention group
Group type: COMPARATOR
Intervention: Glyceryl trinitrate
Number of subjects: 100
Study 2107773 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 100
Study 7468946 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized racemic epinephrine (Micronephrine) at a dose of 0.9 mg/kg body-weight
Number of subjects: 10
Study 7468946 — intervention group
Group type: COMPARATOR
Intervention: Nebulized salbutamol at a dose of 0.15 mg/kg body-weight
Number of subjects: 10
Study 6342641 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg/day
Number of subjects: 8
Study 6342641 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg/day
Number of subjects: 8
Study 6342641 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 640 mg/day
Number of subjects: 8
Study 6342641 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 320 mg/day
Number of subjects: 8
Study 31083192 — intervention group
Group type: EXPERIMENTAL
Intervention: Fu's subcutaneous needling (FSN) combined with usual care (UC) for 4 weeks
Number of subjects: 60
Study 31083192 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) alone for 4 weeks
Number of subjects: 60
Study 31083192 — intervention group
Group type: EXPERIMENTAL
Intervention: FSN combined with UC
Number of subjects: 60
Study 31083192 — intervention group
Group type: COMPARATOR
Intervention: UC alone
Number of subjects: 60
Study 29998338 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 226
Study 29998338 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 226
Study 29998338 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 226
Study 29998338 — intervention group
Group type: COMPARATOR
Intervention: True acupuncture vs Sham acupuncture
Number of subjects: 226
Study 29998338 — intervention group
Group type: COMPARATOR
Intervention: True acupuncture vs Waitlist control
Number of subjects: 226
Study 27522870 — intervention group
Group type: EXPERIMENTAL
Intervention: Caries Management System (CMS)
Number of subjects: 0
Study 27522870 — intervention group
Group type: COMPARATOR
Intervention: Standard dental care
Number of subjects: 0
Study 25085357 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 180 days and Mycophenolate mofetil 95 days (arm 1)
Number of subjects: 208
Study 25085357 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 150 days and Mycophenolate mofetil 180 days (arm 2)
Number of subjects: 208
Study 25085357 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 150 days, Mycophenolate mofetil 180 days and Sirolimus 80 days (arm 3)
Number of subjects: 208
Study 23094314 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene ointment 0.005% applied twice daily
Number of subjects: 27
Study 23094314 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.1% applied twice daily
Number of subjects: 27
Study 23094314 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of calcipotriene and tacrolimus (morning calcipotriene and evening tacrolimus)
Number of subjects: 27
Study 19918980 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (40 KD) plus ribavirin for 48 weeks in genotype 1/4 patients
Number of subjects: 1888
Study 19918980 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (40 KD) plus ribavirin for 24 weeks in genotype 2/3 patients
Number of subjects: 1888
Study 19918980 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (40 KD) plus ribavirin
Number of subjects: 1888
Study 18007570 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline concordant treatments for mixed episodes
Number of subjects: 964
Study 18007570 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline concordant treatments for hypomanic/manic episodes
Number of subjects: 964
Study 18007570 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline concordant treatments for depressive episodes
Number of subjects: 964
Study 16326298 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectilinear biphasic internal defibrillation (group B)
Number of subjects: 134
Study 16326298 — intervention group
Group type: COMPARATOR
Intervention: Monophasic internal defibrillation (group A)
Number of subjects: 134
Study 16326298 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 134
Study 12010266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 20 mg intravenously in the non-operative arm before surgery (systemic presurgery group)
Number of subjects: 47
Study 12010266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 20 mg intravenously to the operative arm after tourniquet inflation (regional presurgery group)
Number of subjects: 47
Study 12010266 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 20 mg intravenously in the non-operative arm after surgery (systemic postsurgery group)
Number of subjects: 47
Study 9443630 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 50
Study 9443630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9086942 — intervention group
Group type: EXPERIMENTAL
Intervention: Community psychiatric nursing (CPN) process
Number of subjects: 8
Study 2714911 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dipyridamole
Number of subjects: 74
Study 2714911 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 74
Study 720738 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaporub
Number of subjects: 56
Study 720738 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum
Number of subjects: 56
Study 720738 — intervention group
Group type: COMPARATOR
Intervention: Healthy children (comparison group)
Number of subjects: 56
Study 31099864 — intervention group
Group type: EXPERIMENTAL
Intervention: Payments from pharmaceutical companies
Number of subjects: 50
Study 27888608 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF plus lumbar drainage (LD)
Number of subjects: 30
Study 27888608 — intervention group
Group type: COMPARATOR
Intervention: IVF alone (control group)
Number of subjects: 30
Study 27888608 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF plus LD
Number of subjects: 30
Study 25856243 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard biofeedback protocol plus daily home use of a Peritron perineometer (intervention)
Number of subjects: 75
Study 25856243 — intervention group
Group type: COMPARATOR
Intervention: Standard biofeedback protocol (control)
Number of subjects: 75
Study 23419231 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 400 mg/d
Number of subjects: 277
Study 23419231 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 600 mg/d
Number of subjects: 277
Study 23419231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study 22379909 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobaric bypivacain (5 mg/ml)
Number of subjects: 38
Study 22379909 — intervention group
Group type: COMPARATOR
Intervention: Ropivacain (5 mg/ml)
Number of subjects: 38
Study 19508650 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training (8 weeks)
Number of subjects: 17
Study 19508650 — intervention group
Group type: COMPARATOR
Intervention: Control group (no plyometric training)
Number of subjects: 17
Study 17845965 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-body screening with multidetector computed tomography
Number of subjects: 50
Study 17845965 — intervention group
Group type: COMPARATOR
Intervention: No screening for 3 years
Number of subjects: 50
Study 15210591 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia (Hb < or =12.0 g/dL)
Number of subjects: 912
Study 15210591 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline hemoglobin (1 g/dL increase)
Number of subjects: 912
Study 15210591 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in hemoglobin over time
Number of subjects: 912
Study 15210591 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in hemoglobin over time
Number of subjects: 912
Study 15210591 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 912
Study 15210591 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA classes
Number of subjects: 912
Study 11202334 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngographic examination of glottis/neoglottis occlusion effectiveness index in patients post-partial laryngectomy.
Number of subjects: 132
Study 11202334 — intervention group
Group type: COMPARATOR
Intervention: Control group (35 subjects).
Number of subjects: 132
Study 8615506 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole-lansoprazole (Group L-L)
Number of subjects: 200
Study 8615506 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole-placebo (Group L-P)
Number of subjects: 200
Study 8615506 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo-lansoprazole (Group P-L)
Number of subjects: 200
Study 8615506 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole-omeprazole (Group O-O)
Number of subjects: 200
Study 8615506 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole-placebo (Group O-P)
Number of subjects: 200
Study 8615506 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo-ranitidine (Group P-R)
Number of subjects: 200
Study 8615506 — intervention group
Group type: COMPARATOR
Intervention: Placebo-placebo (Group P-P)
Number of subjects: 200
Study 1410236 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-oriented intervention (Group 3)
Number of subjects: 168
Study 1410236 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual intervention (Group 2)
Number of subjects: 168
Study 1410236 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (Group 1)
Number of subjects: 168
Study 4009215 — intervention group
Group type: COMPARATOR
Intervention: Involved field radiation treatment (RTIF)
Number of subjects: 108
Study 4009215 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended field radiation treatment (RTEF)
Number of subjects: 108
Study 4009215 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy alone (both RTIF and RTEF)
Number of subjects: 108
Study 30583200 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring (not controlled for positive youth development)
Number of subjects: 2386
Study 30583200 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring (controlled for positive youth development)
Number of subjects: 2386
Study 30286238 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet-based cognitive behavioral therapy for 8 weeks
Number of subjects: 92
Study 30286238 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face clinical care (mean of 2 to 3 appointments)
Number of subjects: 92
Study 30286238 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet-based cognitive behavioral therapy
Number of subjects: 92
Study 30286238 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face clinical care
Number of subjects: 92
Study 28003203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa flavanols (0-820 mg) with methylxanthines (0-220 mg)
Number of subjects: 47
Study 28003203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa flavanols (0-820 mg)
Number of subjects: 47
Study 28003203 — intervention group
Group type: COMPARATOR
Intervention: Methylxanthines alone
Number of subjects: 47
Study 28003203 — intervention group
Group type: COMPARATOR
Intervention: Cocoa flavanols alone
Number of subjects: 47
Study 28003203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa flavanols with methylxanthines
Number of subjects: 47
Study 26408732 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly stopped VEGFR TKI treatment
Number of subjects: 16
Study 26408732 — intervention group
Group type: COMPARATOR
Intervention: Continued VEGFR TKI treatment for another two weeks
Number of subjects: 16
Study 24047919 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg Ca/d
Number of subjects: 372
Study 24047919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 21437445 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation
Number of subjects: 24
Study 21437445 — intervention group
Group type: COMPARATOR
Intervention: T-tube
Number of subjects: 24
Study 21437445 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning success
Number of subjects: 24
Study 21437445 — intervention group
Group type: COMPARATOR
Intervention: Weaning failure
Number of subjects: 24
Study 18205185 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-start zoledronic acid (4 mg intravenously biannually for 5 years)
Number of subjects: 1065
Study 18205185 — intervention group
Group type: COMPARATOR
Intervention: Delayed-start zoledronic acid (4 mg intravenously biannually for 5 years)
Number of subjects: 1065
Study 18205185 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-start zoledronic acid
Number of subjects: 1065
Study 18205185 — intervention group
Group type: COMPARATOR
Intervention: Delayed-start zoledronic acid
Number of subjects: 1065
Study 16443229 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg/day)
Number of subjects: 20